NCT05611593Phase 1Status unknown
Study to Evaluate Safety & Usability of a New Formulation for Male Androgenetic Alopecia
A Phase-I, Open Label, Multi-Centre Clinical Study to Assess the Safety, Tolerability and Usability of FOL100 Lotion in Comparison to Oral Finasteride, for the Treatment of Androgenetic Alopecia
In the register
This trial is not attached to a programme in the register yet. Unattached trials are kept on purpose: they are where new programmes turn up first.
What the registry records
- Status
- Status unknown
- Declared phase
- Phase 1
- Sponsor
- Follicle Pharma Ltd
- Participants (registry)
- 90
- Start
- October 2022
- Primary completion
- December 2024
- Study completion
- February 2025
- Last registry update
- March 2024
- Countries
- Israel
Conditions studied: Androgenic Alopecia
Interventions: FOL100, Propecia 1Mg Tablet, Oral Finasteride
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.